Certain information in this exhibit marked [*] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. CO-MARKETING, MANUFACTURE AND SUPPLY AGREEMENTManufacture and Supply Agreement • March 1st, 2021 • Athenex, Inc. • Pharmaceutical preparations • New York
THIS CO-MARKETING, MANUFACTURE AND SUPPLY AGREEMENT (“Agreement”) is entered into as of November 2, 2020, (“Effective Date”) between INGENUS PHARMACEUTICALS LLC, a Delaware, USA limited liability company with a principal place of business at 4190 Millenia Blvd., Orlando, FL 32839 (“Ingenus”) and ATHENEX PHARMACEUTICAL DIVISION, LLC, a Delaware limited liability company with a principal place of business at 10 Martingale Rd, Suite 230, Schaumburg, IL 60173 (“Athenex”) (hereinafter each a “Party” and collectively referred to as the “Parties”).
ATHENEX, INC. 2017 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENTRestricted Stock Award Agreement • March 1st, 2021 • Athenex, Inc. • Pharmaceutical preparations • Delaware
ASSET PURCHASE AND SALE AGREEMENTAsset Purchase and Sale Agreement • March 1st, 2021 • Athenex, Inc. • Pharmaceutical preparations • New York
THIS ASSET PURCHASE AGREEMENT (this "Agreement") is made and entered into effective as of this 1st day of September, 2020 (the "Effective Date"), by and between Ingenus Pharmaceuticals LLC, a Delaware limited liability company ("Ingenus"), and Athenex Pharmaceutical Division, LLC a Delaware limited liability company ("Buyer") .
